2020 American Transplant Congress
Impact of the Baseline Anti-A/B IgG Titer on the Clinical Outcome in ABO-Incompatible Liver Transplantation
*Purpose: The use of ABO incompatible (ABOi) living donors is an attractive solution for expanding the liver donor pool. We investigated the impact of the…2020 American Transplant Congress
B Cell Depletion with Anti-CD20 mAb Exacerbates Anti-Donor CD4+ T Cell Responses in Highly Sensitized Transplant Model
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen antibodies (DSAs) have been associated with detrimental effects in transplant recipients. To eliminate preformed DSAs, we desensitized DSA-positive recipients…2020 American Transplant Congress
Analyzing Causes for Death-Censored Graft Failure
Charité Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Since it has been proposed that several causes could contribute to graft loss (GL), we analyzed graft failure in our center and attributed a…2020 American Transplant Congress
Can HLA-DQ Molecular Mismatch Analysis Be Used to Predict Generation of De Novo Donor-Specific Antibody at an Individual Patient Level?
1Northwestern University, Chicago, IL, 2SUNY Upstate Medical University, Syracuse, NY
*Purpose: De novo donor-specific antibodies (dnDSA), especially to HLA-DQ, are one of the leading causes of late kidney graft failure. Many investigators have attempted to…2020 American Transplant Congress
Allograft Repopulating Recipient B Cells after Human Intestinal Transplantation and Their Association with Donor Specific Antibody Secretion and Rejection
*Purpose: Alloantibodies produced by recipient B cells are associated with rejection after intestinal transplantation (ITx) and negatively impact patient and graft survival. However, the dynamics…2020 American Transplant Congress
Belatacept Suppresses the B-Cell Alloresponse in the Lower Range of Therapeutic Trough Concentrations
1Plexision, Pittsburgh, PA, 2Bristol-Myers-Squibb, Princeton, NJ
*Purpose: Background: Kidney recipients treated with the T-cell costimulation blocker, belatacept, experience a higher incidence of acute cellular rejection (ACR) and lower incidence of donor-specific…2020 American Transplant Congress
Treatment Strategies to Suppress Donor Specific Antibodies: Highlights from a Decade of Research Experience in a Mouse Model of Allo-Sensitization
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Difficulty in desensitization in highly sensitized patients remain problematic in organ transplantation. For over 12 years, our laboratory has been carrying out an HLA…2020 American Transplant Congress
Desensitization for Deceased Donor Transplantation: Testing a New Paradigm in the Nonhuman Primate
*Purpose: Desensitization regimens have rarely been applied to deceased donor allotransplantation. We hypothesized that belatacept monotherapy during a simulated deceased donor waiting list period would…2020 American Transplant Congress
Blocking Complement Component C3 in a Sensitized Nonhuman Primate Model of Kidney Allotransplantation
*Purpose: Sensitized transplant recipients represent a challenge due to the presence of donor-specific antibodies (DSA), which increase the risk of antibody-mediated rejection. Complement inhibition has…2020 American Transplant Congress
Novel Role of Qa-1, a Murine Homolog of HLA-E, in Controlling Follicular Helper T Cells During Humoral Alloimmunity
*Purpose: Antibody-mediated rejection (AMR) is a major challenge in prolonging allograft survival. Limited insight into the humoral alloimmunity hinders the development of therapeutic strategies. We…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 40
- Next Page »